Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ticagrelor vs standard-dose ticagrelor vs clopidogrel after PCI in moderate/high GRACE risk
ChiCTR2100042709Phase 4Recruiting
- Sponsor
- Hebei University of Engineering
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor and clopidogrel in acute coronary syndrome (ACS), Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (3 arms), sponsored by Hebei University of Engineering. Primary endpoints: Major adverse cardiovascular events (MACE) and Bleeding events. Started Jan 2021; status: recruiting.
02
Drugs
ticagrelorclopidogrel
03
Conditions
acute coronary syndrome (ACS)Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100042709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042709.